Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018 Year: 2019
Ursodeoxy cholic acid (UDCA) reverses hepatotoxicity of multidrug treatment of mycobacterial infections Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2009 - New bronchodilators Year: 2009
Pharmacokinetics of roflumilast and its active metabolite roflumilast N-oxide are not influenced by erythromycin Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Evaluation of early conversion to prolonged-release tacrolimus in lung transplantation. Source: International Congress 2018 – Moving lung transplantation forward Year: 2018
Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Effect of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
The role of azithromycin after lung transplantation Source: Annual Congress 2012 - Non-antibiotic effects of macrolides in lung disease Year: 2012
The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017
Antimicrobial properties of aerosolized liposomal cyclosporine (L-CsA) in lung transplantation patients – An in vitro study Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010
Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Curcumin in combination with low-dose cyclosporine a in experimental airway transplantation Source: Eur Respir J 2007; 30: Suppl. 51, 518s Year: 2007
Highly lipophilic fatty acid esters of the active metabolite of ciclesonide formed in vitro in rat lung tissue Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004